Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT Study.

Introduction: Despite the proven benefits of inhaled corticosteroid (ICS)-containing triple therapy for chronic obstructive pulmonary disease (COPD), clinicians limit patient exposure to ICS due to the risk of pneumonia. However, there are multiple factors associated with the risk of pneumonia in patients with COPD. This post hoc analysis of IMPACT trial data aims to set the risks associated with ICS into a context of specific patient-related factors that contribute to the risk of pneumonia.

Clinical outcome of supervised pulmonary telerehabilitation program among adult patients with post-acute COVID-19 symptoms (PACS): A case series.

Patients with post-acute COVID-19 symptoms (PACS) can present with significant sequela due to the complex systemic effects of COVID-19 infection. Most affected patients have persistent symptoms for 3-12 months after recovery from the acute phase of COVID-19. Dyspnea affecting activities of daily living is one of the most challenging symptoms and has led to an influx of pulmonary rehabilitation (PR) demand.